Holen Sie sich die Stockscreener-App
26.59
4.21%
-1.17
Schlusskurs vom Vortag:
$27.76
Offen:
$29.29
24-Stunden-Volumen:
567.48K
Relative Volume:
2.42
Marktkapitalisierung:
$1.12B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+22.20%
1M Leistung:
+34.36%
6M Leistung:
+292.18%
1J Leistung:
+55.95%
1-Tages-Spanne:
$25.80
$29.73
1-Wochen-Bereich:
$18.33
$29.73
52-Wochen-Spanne:
$5.83
$29.73
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
857-271-2954
Adresse
852 WINTER STREET, SUITE 250, WALTHAM
Vergleichen Sie ZBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
26.59 | 1.31B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-20 | Eingeleitet | Wedbush | Outperform |
| 2025-02-04 | Eingeleitet | Wolfe Research | Outperform |
| 2024-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-05 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-10-08 | Eingeleitet | Citigroup | Buy |
| 2024-10-08 | Eingeleitet | Guggenheim | Buy |
| 2024-10-08 | Eingeleitet | Jefferies | Buy |
| 2024-10-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma Independent Director Acquires 447% More Stock - simplywall.st
Zenas climbs on licensing deal with InnoCare - MSN
Zenas Biopharma stock hits all-time high at 29.29 USD By Investing.com - Investing.com Canada
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) Insider Buys 36,928 Shares of Stock - MarketBeat
Zenas BioPharma (NASDAQ:ZBIO) Director Hongbo Lu Purchases 263,160 Shares - MarketBeat
Fairmount Funds Management Llc Acquires 316,219 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas Biopharma stock hits all-time high at 29.29 USD - Investing.com India
Zenas BioPharma (ZBIO) Is Up 32.5% After Securing Global Rights to Orelabrutinib in MS Deal - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Sets New 1-Year High Following Analyst Upgrade - MarketBeat
Zenas BioPharma Inc Stock Analysis and ForecastSector Rotation Strategies & Watch Expert Picks Before They Rally - earlytimes.in
Will Zenas BioPharma Inc. stock go up soonTrade Entry Summary & Scalable Portfolio Growth Ideas - newser.com
Wedbush Issues Positive Forecast for Zenas BioPharma (NASDAQ:ZBIO) Stock Price - MarketBeat
HC Wainwright Reiterates Buy Rating for Zenas BioPharma (NASDAQ:ZBIO) - MarketBeat
Zenas BioPharma files automatic mixed securities shelf - MSN
Zenas BioPharma: Strategic Licensing and Clinical Advancements Justify Buy Rating - TipRanks
Rx Rundown: Novo Nordisk, Chiesi Group, Zenas Biopharma and more - Medical Marketing and Media
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares By Investing.com - Investing.com South Africa
InnoCare Pharma: Obutinib signs licensing agreement with Zenas BioPharma - iHeart
Insider Buying Spree: Zenas BioPharma Executives Make Bold Moves! - TipRanks
Zenas Biopharma (ZBIO) director Moulder buys $770k in shares - Investing.com India
Lu Hongbo buys Zenas Biopharma (ZBIO) shares worth $6m - Investing.com
Zenas BioPharma rises after Wedbush raises price target - MSN
Zenas BioPharma hits record high as brokerages raise PT - TradingView
Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS - Multiple Sclerosis News Today
Zenas BioPharma: Two Late-Stage Catalysts And A $2B InnoCare Deal (ZBIO) - Seeking Alpha
H.C. Wainwright maintains Zenas Biopharma stock Buy rating on pipeline expansion - Investing.com Canada
Strategic Expansion and Financial Strength Bolster Zenas BioPharma’s Growth Potential: Buy Rating Reaffirmed - TipRanks
Wedbush Raises Price Target on Zenas BioPharma to $40 From $35, Keeps Outperform Rating - MarketScreener
Risk vs reward if holding onto Zenas BioPharma Inc.Earnings Risk Summary & Expert Curated Trade Ideas - newser.com
Should you wait for a breakout in Zenas BioPharma Inc.July 2025 Retail & Risk Adjusted Swing Trade Ideas - newser.com
Zenas BioPharma (Nasdaq:ZBIO) Secures License for Three Autoimmune Candidates Including Orelabrutinib - Kalkine Media
Why Zenas BioPharma (ZBIO) Jumped 17.1% After Announcing $200M Shelf Filing and Major License Talks - simplywall.st
Zenas BioPharma and InnoCare Pharma Announce License - GlobeNewswire
Zenas Biopharma Inc Files For Mixed Shelf- SEC Filing - TradingView
Zenas Looks To Target Progressive Multiple Sclerosis Via InnoCare Deal - insights.citeline.com
Zenas gets global rights for Innocare BTK inhibitor in $2B+ deal - BioWorld MedTech
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug - inkl
Zenas BioPharma (NASDAQ:ZBIO) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Zenas Bio inks potential $2 billion licensing deal with China's InnoCare for autoimmune drug - Reuters
Zenas inks license agreement with InnoCare for 3 autoimmune programs - The Pharma Letter
Zenas looks to China to stock pipeline with 3 more immune drugs - BioPharma Dive
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap UpWhat's Next? - MarketBeat
InnoCare Pharma's US Unit Grants Exclusive License of MS Drug to Zenas BioPharma - 富途牛牛
Zenas climbs on licensing deal with InnoCare (ZBIO:NASDAQ) - Seeking Alpha
Zenas Biopharma stock soars after securing rights to MS drug candidate - Investing.com Australia
Zenas BioPharma Secures Licensing Deal with InnoCare - TipRanks
Waltham company forges $2B deal for MS drug - The Business Journals
InnoCare Pharma says unit entered exclusive license agreement & subscription agreement with Zenas BioPharma - MarketScreener
Zenas Biopharma licenses three autoimmune candidates from InnoCare - Investing.com
InnoCare, Zenas sign global licensing pact worth over $2 bln - MarketScreener
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Es liegen keine Finanzdaten für Zenas Biopharma Inc (ZBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fairmount Funds Management LLC | Director |
Oct 07 '25 |
Buy |
19.00 |
316,219 |
6,008,161 |
2,209,025 |
| Lu Hongbo | Director |
Oct 07 '25 |
Buy |
19.00 |
263,160 |
5,000,040 |
321,983 |
| MOULDER LEON O JR | Chief Executive Officer |
Feb 18 '25 |
Buy |
6.67 |
25,000 |
166,750 |
266,155 |
| Xiao Ting | Director |
Feb 07 '25 |
Buy |
7.76 |
10,000 |
77,600 |
47,000 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 04 '24 |
Buy |
9.98 |
45,000 |
449,100 |
241,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Dec 03 '24 |
Buy |
10.76 |
25,000 |
269,000 |
196,155 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 18 '24 |
Buy |
15.00 |
7,500 |
112,500 |
168,655 |
| MOULDER LEON O JR | Chief Executive Officer |
Nov 19 '24 |
Buy |
14.57 |
2,500 |
36,425 |
171,155 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):